Latin America Bovine Respiratory Disease Treatment Market

Latin America Bovine Respiratory Disease Treatment Market Size

The Latin America Bovine Respiratory Disease Treatment Market is projected to grow from USD 8.37 billion in 2025 to USD 10.66 billion in 2026 and reach USD 74.00 billion by 2034, registering a CAGR of 27.40% from 2026 to 2034.

Bovine Respiratory Disease often mentioned as BRD or "shipping fever," is a composite cattle disease that can be caused by a combination of many causes. BRD can affect the lower or upper respiratory tract in cattle and has serious implications.

Proper cattle management to minimize stress is key to helping avoid Bovine Respiratory Disease, though many stressors such as weather and necessary transport are inevitable. Cattle vaccines and antibiotics can be managed to help avoid or treat viral or bacterial infection. Cattle that have been sick usually gain less, a grade lower and are less efficient. This acts as a huge risk for the market growth.

This research report segmented and sub-segmented the Latin America Bovine Respiratory Disease Treatment Market into the following categories.

By Treatment Type

• Anti-Infectious Agents
  • Antibiotics           
  • Sulfas    
• Anti-Parasiticides                 
• Bronchodilators                    
• Oral Rehydration Fluids                     
• Non-Steroidal Anti-Inflammatories               
• Mucolytics

By Country 

• Brazil
• Mexico
• Argentina
• Chile
• Rest of Latin America

Companies playing a leading role in the Latin American Bovine Respiratory Disease Treatment Market are Zoetis Inc., Merck & Co. Inc., Bayer Corporation, Eli Lilly & Co, Merial S.A.S, Boehringer Ingelheim Vetmedica, Novartis Animal Health, Vibrac S.A., Ceva Sante Animale and Vétoquinol S.A.